Circulating tumor DNA (ctDNA) is a blood test that can be used to detect and monitor thoracic malignancies. It is being used to detect mutations, monitor for recurrence after surgery and other treatments, and can even be used in conjunction with screening to help identify malignancy. As the field continues to advance, it is crucial for thoracic surgeons, trainees, and healthcare providers to stay informed about the latest developments in ctDNA testing and its applications for thoracic patients.
The latest techniques and management strategies in cardiovascular and thoracic critical care and enhanced recovery after surgery for the entire care team.
Learn how to take advantage of everything the STS Annual Meeting has to offer, from educational sessions and networking opportunities. Special focus will be given to trainees and first-time attendees.
The premier annual event in cardiothoracic surgery, unveiling never-before-seen science, techniques, and technology, and creating a forum to build lasting connections with colleagues.
The STS Leadership Institute helps members in their first 15 years of practice to develop the skills necessary to lead teams in and out of the OR, strategize personal and professional goals, negotiate a career path, and influence change in the workplace.
Diversity in the physician workforce is a key component of delivering the best care to our increasingly heterogeneous patient population. The experience of Asians in cardiothoracic surgery is not well known. With a paucity of published evidence, the webinar panel will introduce the topic through the lived experience of Asians in the specialty. The discussion will explore:
Aortic regurgitation is an undertreated condition, often because patients are not referred in a timely fashion for intervention. During this STS webinar, attendees will hear from an expert panel on the evidence base for timing of intervention as well as evolving treatment options. Conventional surgical aortic valve repair can be considered alongside the Ross procedure and transcatheter interventions with dedicated devices. Webinar participants will be better informed on how to treat this patient population.
The management of stage IIIA non-small cell lung cancer (NSCLC) is evolving in the era of immune checkpoint inhibitor therapy. In the past, there has been a great deal of controversy regarding the optimal management of patients with N2 nodal metastasis at the time of diagnosis of NSCLC. There are some new questions to address when considering the results of the Checkmate 816 and the NADIM II clinical trials which demonstrated improved disease-free survival and overall survival with neoadjuvant combined chemotherapy and Nivolumab.